Harbour BioMed deepens ties with Spruce through warrant exercise
Harbour BioMed has transitioned from a traditional licensor to a significant shareholder in Spruce Biosciences, exercising warrants to acquire a nearly 4% stake in the California-based rare disease specialist.










